Carboplatin   -   Antineoplastic platinum compound

  

 Action :

Produces predominantly interstrand DNA crosslinks causing equivalent lesions and biological effects.

  

 Indication :

1st & 2nd line therapy in ovarian carcinoma of epithelial origin.

  

 Pharmaco-Kinetics :

It exhibits linear pharmacokinetics over the dosing range 300 - 500mg / m2. It is not bound to plasma protein but platinum from carboplatin is irreversibly bound to plasma protein.

  

 Contraindication :

History of severe allergic reactions to cisplatin or other platinum compounds or mannitol. Severe bone marrow depression. Significant bleeding.

  

 Adverse-Effects :

Vomiting, thrombocytopenia, raised alkaline phosphates. Abnormally decreased serum electrolyte values. Pain, asthenia.

  

 Special Precaution :

Aluminum can react with carboplatin so do not use needles or I.V. sets containing aluminum parts that may come in contact with carboplatin. High doses can result in severe liver function abnormalities.

  

 Interactions :

Phenytoin

:

Serum concentration may be decreased resulting in loss of therapeutic effect.

  

 Dosage :

Adults

:

I.V. infusion only : 400mg / m2 DSA as single dose over 15 - 60 mins. by infusion; don't repeat for 4 weeks. See literature. 360mg / m2 I.V. every 4 weeks.

  

 Duration of action :

Terminal half-life 5 days.

  

 Strength & Packing :

150mg / 15ml  Injection, 
450mg / 45ml  lnjection.

  
*  for the use of a registered Medical practitioner or a Hospital or a Laboratory only.

  

  

Export Product List


[Go Back to the Export product list]

   
  

   

  

  

Disclaimer : This guide is provided for information purposes only, and for use of a registered medical practitioner or a hospital or a laboratory only. The authors, webmaster, or respective references / links are no way responsible for the content of the information. Although a concerted effort has been made to ensure the validity of the information contained in this document, we give no assurance for the accuracy of the information in this documents.